Fig. 4. Talin and β₁ integrin in a ligand-binding form accumulate at both peripheral and central FAs regardless of treatment with blebbistatin. (A-F) Cells grown on FN were treated with (D-F) or without (A-C) 100 µM blebbistatin for 30 minutes, and then fixed and double stained for ₅ integrin (A,D, green in C,F) and talin (B,E, red in C,F). (G-J) Cells treated with (I,J) or without (G,H) 100 µM blebbistatin for 30 minutes were fixed and double stained with anti-₅-integrin antibody (G,I) and mAb B44, which recognizes the ligand-induced binding site (LIBS) on β₁ integrin (H,J). Scale bars: 20 µm.